Friday, Jan 25, 2019
News Recap:
Using Telemedicine HCV Care Model in Prisons in SPAIN
“HCV telemedicine program satisfying, cost-effective in Spanish prison: A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018…” Read more about Spain’s prison-based HCV “Telemedicine” treatment model.
Saturday in Surrey! Visit HepC
HepCBC is quite interested in NASH because people with hepatitis C are particularly vulnerable to NASH, even after being cured of hepatitis C! (Reference for relation between post-SVR HCV and NASH: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859229/)
Register for free CCO webinar: “Identifying and Managing NASH [Non-alcoholic steatohepatitis] in High-Risk Populations: A Silent Epidemic, NASH affects 30 million Americans, or 12% of all adults. By 202
Friday, April 27, 2018
News Recap:
Warnings:
Synthetic cannabinoids and Hepatitis A could be a fatal combination. On April 9, 2018, the Missouri Department of Health and Senior Services (DHSS) issued a news release – “Use of Synthetic Cannabinoids Linked to Severe Bleeding in the US,” informing the public about the national outbreak of bleeding illnesses among those consuming synthetic cannabinoids which appear to have been contaminated with a long-...
11 April 2018, Paris, France: Two independent studies have today reported that alcoholic liver disease has now replaced hepatitis C virus (HCV) infection as the leading cause of liver transplantation in the USA in patients without HCC. Non-alcoholic steatohepatitis (NASH) is also on the increase, now ranking second as a cause of liver transplantation due to chronic liver disease.
Chronic HCV infection has remained the leading indication for liver transpla...